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OBJECTIVES This study evaluated long-term survival and predictors of elevated risk for young adults
diagnosed with coronary artery disease (CAD).
BACKGROUND Coronary artery disease is rarely seen in young adults. Traditional cardiac risk factors have
been studied in small series; however, many questions exist.
METHODS We identified 843 patients under age 40 with CAD diagnosed by coronary angiography from
1975 to 1985. Death, hypertension, gender, family history, prior myocardial infarction (MI),
diabetes, heart failure, angina class, number of diseased vessels, ejection fraction (EF),
Q-wave infarction, in-hospital death, and initial therapy were studied. Patients were followed
for 15 years.
RESULTS The mean age was 35 for women (n  94) and 36 for men (n  729). The average EF was
55%. Fifty-eight percent of the subjects had single-vessel disease, and 10% were diabetic. The
strongest predictors of long-term mortality were a prior MI (hazard ratio [HR] 1.32, 95%
confidence interval [CI] 1.00 to 1.73), New York Heart Association class II heart failure
(HR 1.75, 95% CI 1.03 to 2.97), and active tobacco use (HR 1.59, 95% CI 1.14 to 2.21).
Revascularization, rather than medical therapy, was associated with lower mortality (coronary
angioplasty: HR 0.51, 95% CI 0.32 to 0.81; coronary artery bypass graft: HR 0.68, 95% CI
0.50 to 0.94). Overall mortality was 30% at 15 years. Patients with diabetes had 15-year
mortality of 65%. Those with prior MI had 15-year mortality of 45%, and patients with an
EF 30% a mortality of 83% at 15 years.
CONCLUSIONS Coronary disease in young adults can carry a poor long-term prognosis. A prior MI, diabetes,
active tobacco abuse, and lower EF predict a significantly higher mortality. (J Am Coll
Cardiol 2003;41:521–8) © 2003 by the American College of Cardiology Foundation
Coronary artery disease (CAD) is predominately manifest
in older individuals, but the disease process begins in the
young. Although the prevalence of coronary atherosclerosis
in young adults is difficult to estimate, there are data on the
risk of developing CAD at an older age based on risk factors
present while young (1). Although myocardial infarction
(MI) registries estimate that 2% to 6% of all infarctions
involve individuals under the age of 45 (2), autopsies of
young adults under the age of 34 have shown that 50% have
intimal atherosclerosis (3). Prior literature emphasizes that
cigarette smoking, cocaine use (4–6), diabetes, and dyslip-
idemia are prominent risk factors in the development of
early atherosclerosis (1,2,4–15).
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Small studies comparing younger and older patients with
MI show that young patients are discharged with higher
ejection fractions (EF), have fewer comorbidities, and are
more likely to return to work (7). Also, short-term mortality
studies indicate that these patients have a more favorable
outcome (2,7,9,11,12).
Even with this information, however, many questions
regarding young patients with CAD still exist. For instance,
little data exist regarding follow-up beyond 10 years, and the
effect of treatment strategies on mortality has not been
definitively reported. Multivariate analysis of risk factors as
correlates of long-term mortality has not been done in a
large series. In order to better study these issues, we
identified a large population of young individuals with
angiographically proven CAD.
METHODS
The Emory Cardiac Database was retrospectively queried to
identify patients treated between 1975 and 1985, who were
under the age of 40 and who had a minimum of one
angiographically documented coronary artery stenosis
50%. Follow-up data from the last 15 years were analyzed
to address cardiovascular morbidity and mortality.
Data collection. All data were collected on standardized
forms and subsequently entered into a computerized data-
base. Initial evaluations were made by clinical staff. At the
time of presentation, patients underwent history and phys-
ical examination by a physician. Patient variables recorded
included gender, age, family history of CAD in first-degree
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relatives before age 50, hypertension (defined by current or
previous therapy or history of blood pressure 140/95),
prior MI (by history), and history of and type of diabetes
mellitus. Diabetes was defined by ongoing oral or insulin
therapy or diet control, provided the clinician also had
laboratory evidence of hyperglycemia. Each patient was also
classified as a nonsmoker, active smoker, or former smoker,
defined as no smoking in at least three months. Angina class
was based on the Canadian classification (16) and heart
failure was defined by New York Heart Association criteria
(17). Electrocardiography diagnosis of Q-wave infarction
was determined at initial presentation. All patients included
in the study underwent angiography. Angiographers made a
subjective assessment of EF and extent of coronary stenosis.
Cases of inpatient mortality were recorded. Fifteen years of
follow-up data were obtained by telephone interview and
hospital encounters.
Statistical analysis. Categorical data were displayed as
proportions and continuous data as mean  SD. Categor-
ical data were compared using chi-squared. Continuous data
in two groups were compared using unpaired t test, and
between multiple groups using analysis of variance. Survival
over 15 years of follow-up was displayed using the Kaplan-
Meier method, with comparison between groups by gener-
alized Wilcoxon rank-sum. Correlates of long-term survival
were determined by Cox model analysis. All p values were
two-tailed and values of 0.05 were considered statistically
significant. All confidence intervals (CIs) were calculated to
the 95th percentile. Comparisons of clinical characteristics
were made between women and men, diabetic and nondi-
abetic patients, and those treated with medical therapy,
percutaneous transluminal coronary angioplasty, or coronary
artery bypass graft surgery (CABG). In the long-term
survival model, variables defined were age, gender, presence
of hypertension, prior MI, diabetes, heart failure, angina
class, EF, active tobacco use, former tobacco use, number of
diseased vessels, left main disease, Q-wave infarction, and
in-hospital death. Each of these variables was considered a
potential correlate of long-term mortality, and hazard ratios
(HRs) were calculated on the basis of the backward-
elimination Cox model. Finally, mode of initial therapy was
entered into the model. This variable, which is most subject
to selection bias, was considered separately so that analysis
could be performed either with or without consideration of
initial treatment.
RESULTS
Initial characteristics and in-hospital mortality. We
identified 843 patients under the age of 40 with CAD
documented by coronary angiography. Though full details
of the initial admission were not available for all patients,
the most common presenting diagnoses included chest pain,
abnormal stress test, and unstable angina. Only 2% of the
patients presented with acute MI. Complete characteristics
of the cohort, divided by gender, are shown in Table 1.
Eleven percent of the patients were women. The mean age
at presentation was 35 for women and 36 for men. The
average EF in the study was 55% to 57%. Approximately
one-half of the patients had prior MI (51% to 57%) at the
time of initial admission. Smoking was a common risk
factor; current and former smokers represented the majority
of the patients (65%). Interestingly, 81% of the nonsmokers
had a family history of CAD versus 53% and 57% of the
smokers and former smokers (p  0.0001). Active smokers
(36% of the patient population) were more likely to have
angina than the former smokers or nonsmokers (53% vs.
41% to 42%; p  0.03). The active smokers did not have
statistically higher rates of in-hospital mortality or Q-wave
infarction. Men and women predominately had single-
vessel disease (55% to 60%) and a similar distribution of
diseased vessels. Only 2% of the patients had left main
disease. Ten percent of the patients with CAD were
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CI  confidence interval
EF  ejection fraction
HR  hazard ratio
MI  myocardial infarction
Table 1. Clinical Characteristics
Women
(n  94)
Men
(n  729) p Value
Age 35  4 36  3 0.2
Family history 65 (69.1%) 461 (63.4%) 0.33
Systemic hypertension 38 (41.8%)
(n  91)
187 (27.1%)
(n  689)
0.006
Prior MI 46 (51.1%) 405 (57.7%) 0.28
Diabetes 24 (26.4%)
(n  91)
55 (8%)
(n  687)
 0.0001
Insulin dependent 15 (93.8%)
(n  16)
26 (72.2%)
(n  36)
0.17
Never smoked 34 (36.2%) 250 (34.3%) 0.81
Former smoker 24 (25.5%) 220 (30.2%) 0.42
Current smoker 36 (38.3%) 259 (35.5%) 0.68
Heart failure 5 (5.7%)
(n  87)
35 (5.3%)
(n  666)
0.85
Class 3–4 angina 36 (52.2%)
(n  69)
221 (45.6%)
(n  485)
0.37
Ejection fraction 57  17
(n  75)
55  15
(n  570)
0.24
1-vessel disease 57 (60.6%) 407 (55.8%) 0.44
2-vessel disease 23 (24.5%) 198 (27.2%) 0.67
3-vessel disease 12 (12.8%) 108 (14.8%) 0.71
Left main disease 2 (2.1%) 16 (2.2%) 0.97
Medical therapy 37 (39.4%) 286 (39.2%) 0.98
PTCA 26 (27.7%) 195 (26.7%) 0.95
CABG 31 (33%) 248 (34%) 0.93
Q-wave MI 1 (1.06%) 15 (2.06%) 0.79
Death in hospital 1 (1.11%)
(n  90)
2 (0.3%)
(n  676)
0.79
CABG  coronary artery bypass grafting; MI  myocardial infarction; PTCA 
percutaneous transluminal coronary angioplasty
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diabetic, including a significantly higher percentage of the
women (30% women were diabetic vs. 9% men, p 
0.0001). The available information on the diabetics revealed
that 93% of the women and 72% of the men were on insulin.
A family history of early CAD was present in 60% to 70%
of the group.
Because of the known significant risk of early CAD in
diabetic patients, clinical characteristics were compared
between diabetic and nondiabetic patients, with results
detailed in Table 2. Briefly, diabetic patients were more
likely to have hypertension (50% vs. 25%; p  0.0001) or
heart failure (14% vs. 4.3%; p  0.001), and were more
likely to have suffered a Q-wave infarction (6.33% vs.
1.14%; p  0.003). Both groups had a low risk of death
while in the hospital (1%).
In order to evaluate patients on the basis of initial
treatment, clinical characteristics and in-hospital mortality
of patients treated with medical therapy, coronary angio-
plasty, and CABG are presented in Table 3. This “initial
treatment” reflects the initial treatment decision after an-
giography. All three treatment groups had very low in-
hospital mortality. Given the options available, treatment
was appropriate by current recommendations. Eighty-six
percent of the insulin-requiring patients underwent CABG
or medical therapy. Eighty percent of the patients referred
for coronary angioplasty had single-vessel disease (p 
0.0001) and 67% undergoing CABG had two- or three-
vessel disease (p  0.0001). Ejection fraction was similar
across the treatment groups (52% to 60%). Patients with
heart failure on admission were more likely to undergo
initial medical therapy versus revascularization (p 0.0005).
Table 2. Clinical Characteristics
No Diabetes
(n  699)
Diabetes
(n  79) p Value
Age 36  3 35  4 0.05
Women 67 (9.6%) 24 (30.4%)  0.0001
Family history 437 (62.5%) 53 (67.1%) 0.5
Systemic hypertension 179 (25.8%) 39 (50.6%)  0.0001
Prior MI 387 (56.1%) 48 (61.5%) 0.42
Never smoked 215 (30.8%) 32 (40.5%) 0.1
Former smoker 216 (30.9%) 24 (30.4%) 0.92
Current smoker 268 (38.3%) 23 (29.1%) 0.14
Heart failure 29 (4.3%) 10 (14.1%) 0.001
(n  670) (n  71)
Class 3–4 angina 226 (45.7%) 30 (54.5%) 0.27
(n  494) (n  55)
Ejection fraction 55  15 53  17 0.29
(n  553) (n  61)
1-vessel disease 411 (58.8%) 37 (46.8%) 0.06
2-vessel disease 180 (25.8%) 23 (29.1%) 0.61
3-vessel disease 95 (13.6%) 17 (21.5%) 0.08
Left main disease 13 (1.9%) 2 (2.5%) 0.68
Medical therapy 275 (39.3%) 36 (45.6%) 0.34
PTCA 204 (29.2%) 17 (21.5%) 0.19
CABG 220 (31.5%) 26 (32.9%) 0.89
Q-wave MI 8 (1.14%) 5 (6.33%) 0.003
Death in hospital 2 (0.31%) 0 (0%) 0.63
(n  649) (n  75)
Abbreviation as in Table 1.
Table 3. Clinical Characteristics
Medicine
(n  323)
PTCA
(n  221)
CABG
(n  279) p Value
Age 36  3 36  3 36  3 0.52
Women 37 (11.5%) 26 (11.8%) 31 (11.1%) 0.97
Family history 207 (64.5%) 127 (57.5%) 192 (68.8%) 0.03
Systemic hypertension 89 (28.5%)
(n  312)
58 (26.2%)
(n  221)
78 (31.6%)
(n  247)
0.44
Prior MI 230 (73.5%)
(n  313)
67 (30.3%)
(n  221)
154 (59.7%)
(n  258)
 0.0001
Diabetes 36 (11.6%)
(n  311)
17 (7.7%)
(n  221)
26 (10.6%)
(n  246)
0.33
Insulin dependent 19 (86.4%)
(n  22)
9 (60%)
(n  15)
13 (86.7%)
(n  15)
0.11
Never smoked 100 (31%) 49 (22.2%) 135 (48.4%)  0.0001
Former smoker 93 (28.8%) 99 (44.8%) 52 (18.6%)  0.0001
Current smoker 130 (40.2%) 73 (33%) 92 (33%) 0.11
Heart failure 28 (9.2%)
(n  304)
6 (2.7%)
(n  219)
6 (2.6%)
(n  230)
0.0005
Class 3–4 angina 88 (44.7%)
(n  197)
97 (46%)
(n  211)
72 (49.3%)
(n  146)
0.69
Ejection fraction 52  16
(n  307)
60  12
(n  84)
57  14
(n  254)
0.0001
1-vessel disease 208 (64.4%) 178 (80.5%) 78 (28%)  0.0001
2-vessel disease 79 (24.5%) 41 (18.6%) 101 (36.2%)  0.0001
3-vessel disease 32 (9.9%) 2 (0.9%) 86 (30.8%)  0.0001
Left main disease 4 (1.2%) 0 (0%) 14 (5%) 0.0002
Q-wave MI 0 (0%) 5 (2.26%) 11 (3.94%) 0.002
Death in hospital 1 (0.38%)
(n  266)
1 (0.45%)
(n  221)
1 (0.36%)
(n  279)
0.98
Abbreviation as in Table 1.
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Compared with the other two groups, patients undergoing
coronary angioplasty were less likely to have a prior history of
infarction (30% vs. 60% to 74%; p  0.0001).
Long-term mortality. Follow-up was obtained for 823 of
the 843 patients. At 15 years, 253 of the patients with
follow-up had died (31%), but subgroup analysis was able to
demonstrate certain elements of the study population with
greater risk. As shown in Figure 1, diabetic patients had a
15-year survival of only 35%, with a survival curve that
diverged from nondiabetic patients by year 2. Analysis of
other subgroups demonstrated increased mortality for the
451 patients with prior MI, starting at six years and further
increasing over the 15 years (Fig. 2). Although the number
of individuals with an EF 30% was low, their mortality
was 72% at 11 years (Fig. 3). Thus, in our analysis, diabetic
patients had a long-term survival comparable to the group
with an EF 30%.
Next, outcomes were analyzed on the basis on initial
treatment strategy. Figure 4 shows that freedom from a new
MI was equivalent for the three treatment groups until year
8, when 23% of the CABG patients had an MI, a value that
increased to 33% by year 10. The angioplasty group had the
lowest number of second infarcts, with 27% having an event
at 15 years versus 33% in the medical group (p  0.0001)
and 40% in the CABG group (p  0.0001). Also, 26% of
the medically treated patients eventually required CABG by
six years compared with 12% of the angioplasty group (p 
0.09).
Cox proportional hazard model. In order to evaluate
individual hazards of long-term mortality, a Cox propor-
tional hazard model was developed for long-term mortality,
with results detailed in Table 4. The initial model included
all presenting clinical characteristics as potential covariates
of mortality, and the strongest predictors of long-term
mortality were active tobacco use (HR 1.59; 95% CI 1.14 to
2.21) and New York Heart Association class II heart failure
(HR 1.75; 95% CI 1.03 to 2.97). As anticipated, diabetic
patients also had a significantly worse prognosis (HR 1.41;
95% CI 1.04 to 1.90). Worsening EF was also correlated
with poor prognosis (HR 1.3; 95% CI 1.19 to 1.43, for each
10% drop in EF). Importantly, age, gender, hypertension,
angina class, and number of diseased vessels were not
statistically significant predictors of long-term mortality.
Next, choice of initial therapy was added to the model, and
patients undergoing either revascularization option had a
substantially lower mortality compared to medical therapy
(two-way comparisons: angioplasty vs. medical therapy, HR
0.51; 95% CI 0.32 to 0.81, and CABG vs. medical therapy,
HR 0.68; 95% CI 0.50 to 0.94). Hazard ratios for other
covariates were little changed.
DISCUSSION
The study of CAD in young individuals is important in the
current era of preventive cardiology. The 823 patients
Figure 1. Survival in diabetic and nondiabetic patients. The increase in diabetic mortality starts in the first year after angiography and continues over the
15 years of follow-up (p  0.0001). After 15 years only 35% of the diabetic patients had survived.
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Figure 2. Survival for patients with a prior myocardial infarction (MI) versus no prior MI. A significant increase in mortality is seen starting after the second
year for the individuals with a prior MI, and they had 45% mortality at 15 years (p  0.0001).
Figure 3. Fifteen-year survival for patients categorized by ejection fractions (EFs)30%, 30%–49%, and50%. Patients with an EF30% had a dramatic
mortality increase during the first year of follow-up, and only 17% were alive at 15 years (p  0.0001 for differences across the three groups of therapy).
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detailed here represent the largest described series of docu-
mented patients with CAD under the age of 40. The large
sample size allows new insights into the dramatic mortality
of this group and identifies specific risk factors that predict
individuals at a higher mortality risk. We also provide
long-term follow-up data on three large treatment groups.
Some have identified current tobacco use as the most
common risk factor in young MI patients. These studies
reported that between 76% and 90% of young patients with
MI are smokers compared with 40% of older patients with
MI (10,11). Others have reported that only 8% of MI
patients under the age of 45 did not smoke (12). Also,
smoking is a notable risk factor for the development of fatty
streaks in the aortas and coronary arteries of young autopsy
patients (13). In our study, active and former smokers
represented 65% of the patients. Smoking was not only a
prevalent risk factor, but its presence was an important
predictor of long-term mortality regardless of treatment
strategy. Importantly, former smokers did not have a sig-
nificant increase in their long-term mortality compared with
those who had never smoked. Our data provide strong
epidemiologic support to findings that show a decline in
mortality with smoking cessation.
As would be expected on the basis of smaller observa-
tional studies, diabetes, which was present in 10% of our
patients, was a significant marker for mortality risk. Inter-
estingly, a much higher percentage of the women were
diabetic. Most of the diabetic patients required insulin, and
they also had greater cardiovascular morbidity, including
Q-wave infarction and heart failure. Although in-hospital
mortality rates were low, diabetes was a significant negative
predictor of survival, as the diabetic patients had an unad-
justed mortality of 65% at 15 years. Also, mode of treatment
did not change their risk. This information confirms the
importance of diabetes as a predictor of cardiac mortality,
Figure 4. Freedom from myocardial infarction (MI) based on initial therapy. The coronary bypass patients had the highest rates of MI starting around year
8, reflecting the time of expected vein graft loss (p  0.04 for differences in survival across three initial therapy groups).
Table 4. Correlates of Long-Term Mortality for All Patients
HR 95% CI p Value
Prior MI 1.32 1.00 to 1.73 0.0492
Class II heart failure 1.75 1.03 to 2.97 0.0375
Class III heart failure 1.07 0.47 to 2.43 0.8730
Class IV heart failure 15.00 2.43 to 92.38 0.0035
Former smoker 1.12 0.77 to 1.64 0.5590
Current smoker 1.59 1.14 to 2.21 0.0056
Diabetes 1.41 1.04 to 1.90 0.0258
Ejection fraction (10% decrease) 1.30 1.19 to 1.43  0.0001
Correlates of Long-Term Mortality, Initial Therapy Included
Prior MI 1.21 0.91 to 1.62 0.1830
Class II heart failure 1.82 1.07 to 3.08 0.0267
Class III heart failure 1.07 0.49 to 2.32 0.8660
Class IV heart failure 11.87 2.21 to 63.81 0.0039
Former smoker 1.13 0.77 to 1.66 0.5380
Current smoker 1.54 1.11 to 2.15 0.0105
Diabetes 1.47 1.09 to 1.98 0.0107
Ejection fraction (10% decrease) 1.30 1.18 to 1.42  0.0001
PTCA compared to medicine 0.51 0.32 to 0.81 0.0040
CABG compared to medicine 0.68 0.50 to 0.94 0.0178
HR  hazard ratio. Other abbreviations as in Table 1.
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something that has been shown both in primary (18) and
secondary prevention patients (19,20).
Ejection fraction is another well-known predictor of
cardiovascular mortality (21–24). Our analysis confirms this
point in young adults as well. Even though the average EF
in our study was between 55% and 57%, for every 10% drop
in EF, there was a substantial mortality increase. Further-
more, because of the inclusion criteria for our dataset, our
analysis is relatively specific to ischemic cardiomyopathy. Of
our patients with an EF 40%, only one did not have a
prior MI. Although medical therapy has changed since the
time of initial data inclusion, the mortality for the young
patients with an ischemic cardiomyopathy was tremendous.
Smaller studies have shown that patients with lower EFs
and residual myocardial ischemia benefit from revascular-
ization (25–27); however, the inclusion of mode of therapy
as a covariate does not eliminate the profound hazard associ-
ated with low EF: an uncorrected 10-year mortality of 80%.
Our study provides 15 years of observational follow-up on
three large treatment groups. Revascularization in young pa-
tients has been examined in small patient populations with
varying results. Kofflard reported that angioplasty patients
under the age of 35 had low infarct rates and excellent graft
patency, but higher rates of repeat revascularization (28). Also,
young patients undergoing CABG have been shown to have
excellent short-term survival (29). One study of 125 patients
under the age of 40 reported a mortality rate of 5.2% at 4.5
years (30). However, others have disputed this finding (31),
and another showed patients to have a 75% and 50% survival
at 10 and 15 years, respectively (32). In our large cohort, the
angioplasty and CABG patients had a much lower long-term
mortality (HR 0.51 and 0.68, respectively) than the medically
treated group. During the first year after admission, the
angioplasty patients had the highest rates of repeat revascular-
ization, likely reflecting the high degree of restenosis in the
pre-stent era. Also, medically treated patients were more likely
to undergo CABG if revascularization were required. The
CABG group had the highest rate of recurrent MI around the
time of expected graft loss (year 8), yet they still had the lowest
long-term mortality. Although selection bias cannot be over-
come in the absence of randomization, our data illustrate that
young individuals can benefit from revascularization.
The most striking finding of our study is the overall poor
prognosis of individuals with premature CAD. Although
only one patient in each treatment group died during the
initial hospitalization, there was a 15-year mortality of 30%.
Even considering differences in study design and patient
characteristics, our analysis differs significantly with prior
reports. In GISSI-2, an analysis of patients under age 50
showed them to have a low in-hospital and short-term
mortality (33). Other studies also note low mortalities in
follow-up of six months (2.7%) and longer to seven years
(16%) (10,11). We demonstrate a mortality increase after
the time period defined in other studies (8,10,32). Also,
even though other studies required an MI as admission
criteria, not all patients underwent angiography. Of note,
data show that 20% of young adults may have non-
atherosclerotic infarctions (34) and have a more favorable
prognosis than individuals with arteriosclerosis (35). Finally,
it is also important to recognize that our study reflects a
tertiary referral center patient population.
Limitations of our investigation reflect a lack of under-
standing about the vascular biology of atherosclerosis at the
time of initial data collection. Unfortunately, the impor-
tance of cholesterol as a coronary risk factor was not fully
appreciated into the mid-1980s, and we do not have data on
patient lipid levels. We also do not have documentation of
specific medication therapy. Angiotensin-converting en-
zyme inhibitors, beta-blockers, and anti-lipemic medica-
tions have all been accepted into the treatment regimen of
these patients since our cohort was first identified. It would
also be ideal if there were documentation of other risk
factors, such as cocaine abuse, but this information is not
available. Many of our patients had a family history of
CAD, and this is a prominent risk factor documented in
other studies (2,29,32,36). It would be ideal to obtain
follow-up on these patients’ children, as there are emerging
data regarding the genetics of atherosclerosis. Recent data
show that even healthy individuals with a family history of
premature CAD have abnormal endothelial function re-
flecting early arterial pathology (37). In the future, we may
find that atherosclerosis manifesting in young patients
reflects a different disease process than in older individuals.
Further investigation incorporating a modern understand-
ing of oxidative stress, endothelial dysfunction, inflamma-
tory markers, and lipid subtypes may better define the
vascular biology and additional markers of future risk.
For now, however, clinicians must focus on the modifi-
cation of known risk factors for CAD, and our study
demonstrates the importance of these risk factors—
particularly cigarette smoking and diabetes—in young
adults. Finally, when a physician sees a young patient with
documented CAD, the mortality demonstrated in our
cohort gives a particular sense of urgency to treatment
decisions, along with a possible bias toward revasculariza-
tion if clinically appropriate. Our data also provide strong
motivation for more continued aggressive study into the
pathophysiology of CAD in this patient group.
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